Adverse Effects Associated with SBRT in Patients With HCC

Opinion
Video

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.

Recent Videos
Related Content
Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.

Real-world Data Supports Findings from FIGHT-202 in Cholangiocarcinoma

Harrison Widelitz
September 26th 2024
Article

Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.

Tremelimumab Combo Improves OS Vs Sorafenib in Unresectable Liver Cancer

Morgan Bayer
September 17th 2024
Article

Treatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.

Single-Fraction Radiotherapy Improves Pain in Hepatic Cancer

Harrison Widelitz
September 16th 2024
Article

Data from CCTG HE1 also show a numerical improvement an in overall survival with added radiotherapy over best supportive care alone.

The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.

FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable Liver Cancer

Russ Conroy
August 21st 2024
Article

The FDA has set a Prescription Drug User Fee Act date of April 21, 2025, for the potential approval of frontline nivolumab/ipilimumab in unresectable HCC.

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.

EMA Validates Application for Nivolumab/Ipilimumab in Liver Cancer Type

Roman Fabbricatore
July 22nd 2024
Article

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.